Mateon Therapeutics Inc (OTCMKTS:MATN),one of the biotech Stocks has announced breakthrough in four of its syngeneic mouse models studying the company’s drug CA4P together with checkpoint inhibitors. Mateon Therapeutics is a biopharmaceutical company involved in development and commercialization of vascular disrupting agents (VDAs) that is used in treatment of signs of orphan oncology. The company now joins the list of biotech Stocks that have been announcing major breakthrough clinical studies.
The most outstanding results were reported from a combination of CA4P from Mateon with an anti-CTLA4 antibody. During the study, seven out of the eight subjected to the treatment showed no signs of tumor at the end of the study. This is a divergent from the one out of eight subjected to the CA4P monotherapy arm and two out of eight recorded in the anti-CTLA4 antibody study.
Out of the four follow-up showed that a combination of CA4P and immune oncology agents decelerated the rate of growth of the tumor. The studies were carried out in a very big C3H mammary model, EMT-6 mammary model and a CT26 colon model. The results from the study offer more supportive proof that CA4P boosts the anti-CTLA4 antibody activity. It also support the inference that CA4P boosts anti-PD-1 and PD-L1 activity.
Mateon President and Chief Executive Officer William D. Schwieterman confirmed that in several previous studies, the CA4P through vascular disruption leads to extensive and rapid necrotic tumor cell death. He adds that by causing necrotic tumor cell death, it can be inferred that CA4P may boost T-cell activity within the tumors, a case which may the effects of checkpoint inhibitors in tumors more pronounced. William says basing these results, they will continue with additional studied in the field.
Mateon Therapeutics, Inc. is Biopharmaceutical Company working to achieve the full potential of vascular targeted therapy (VTT) in oncology. The vascular targeted therapy includes vascular disrupting agents (VDAs) like investigational drugs developed by Mateon as well as angiogenic agents (AAs), some of which have been approved by FDA and extensively used in the treatment of cancer. The two approaches have different yet interdependent mechanisms of action.